Manchester Capital Management’s Editas Medicine EDIT Stock Holding History

Manchester Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,000	Closed	-$31.2K	–	1026
2023 Q3	$31.2K	Hold	4,000	–	–	﹤0.01%	473
2023 Q2	$32.9K	Hold	4,000	–	–	﹤0.01%	451
2023 Q1	$29K	Hold	4,000	–	–	﹤0.01%	467
2022 Q4	$35.5K	Hold	4,000	–	–	0.01%	388
2022 Q3	$49K	Hold	4,000	–	–	0.01%	361
2022 Q2	$47K	Buy	4,000 +2,000	+100%	+$26.8K	0.01%	367
2022 Q1	$38K	Hold	2,000	–	–	0.01%	416
2021 Q4	$53K	Hold	2,000	–	–	0.01%	399
2021 Q3	$82K	Buy	+2,000	New	+$110K	0.01%	379
2019 Q2	–	Sell	-275	Closed	-$7K	–	576
2019 Q1	$7K	Buy	+275	New	+$6.22K	﹤0.01%	584

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Manchester Capital Management's EDIT Position: Q4 2023 in Review

Manchester Capital Management sold out of Editas Medicine (EDIT) in Q4 2023, closing a stake of 4,000 shares — an estimated $31.2K sold.

Manchester Capital Management first reported a position in EDIT in Q1 2019 and held it in 10 quarters. The position peaked at $82K in Q3 2021. 225 funds tracked by Wall St. Rank hold EDIT as of Q4 2023.

Manchester Capital Management reported no remaining Editas Medicine position as of Q4 2023 after selling out during the quarter.
Manchester Capital Management sold 4,000 Editas Medicine shares in Q4 2023, an estimated $31.2K.
Manchester Capital Management first reported a position in Editas Medicine in Q1 2019 and held it in 10 quarters.
Manchester Capital Management's Editas Medicine position peaked at $82K in Q3 2021.
225 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2023.

Based on Manchester Capital Management's 13F filing for Q4 2023, filed 8 Feb 2024.